An in-depth assessment of PET/CT at three German teaching hospitals has shown the fusion imaging technology improves on CT alone and pays dividends clinically and financially for staging non-small cell lung cancer.
The research leading to these conclusions was based on evaluations of 205 patients with proven non-small cell lung cancer who were staged with FDG-PET/CT and conventional contrast-enhanced imaging with only the CT component of the hybrid scanner. Follow-up was performed five years after staging to assess survival and clinical status.
Patients were imaged at the Technical University Munich, University of Ulm, and Technical University Berlin, all in Germany. Results were presented at the 2008 SNM meeting in June by principal investigator Dr. Andreas Buck, a researcher in the nuclear medicine department at Technical University Munich.
"This is the first study indicating that PET/CT leads to an increase of survival in NSCLC patients due to more precise description of the tumor stage at initial presentation," said Dr. Markus Schwaiger, dean of the Technical University Munich and a contributor to the study.
The combined PET/CT approach improved diagnostic accuracy and altered therapy decisions. Study subjects evaluated with PET/CT also survived longer than those who were not examined with fusion imaging technology.
PET/CT was more accurate than CT alone for tumor, nodal, and metastatic staging. CT alone led to seven false T-stage readings, compared with none for PET/CT. CT alone contributed to 28 false N-stage findings, compared with three for PET/CT, and it found distant metastases in 28% of patients compared with the 35% of patients in whom PET/CT found such metastases.
The PET/CT studies led investigators to downstage 21 patients (10.2%), which, in turn, led to recommendations for 13 additional surgical procedures. Fourteen patients were upstaged, leading to the cancellation of nine surgeries.The mean survival of patients staged with PET/CT was 957 days, compared with 453 days for patients staged with CT alone.
The cost of an additional quality-adjusted life year, including diagnosis and treatment, was assessed at $81,762 (about €52,000), according to the study, which was considerably less than the $147,980 (about €100,000) considered the ceiling for a cost-effective diagnosis, Buck said. It cost an average of $4330 to correctly stage a tumor using PET/CT.
"This demonstration of cost-effectiveness helps to further establish PET/CT as standard for tumor staging, not only for lung cancer, but also for other malignancies," Schwaiger said.
--By Alison Fromme
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
The Reading Room Podcast: A Closer Look at Remote MRI Safety, Part 2
July 25th 2025In the second of a multi-part podcast episode, Emanuel Kanal, M.D. and Tobias Gilk, MRSO, MRSE, share their perspectives on remote MRI safety protocols for ensuring screening accuracy and adherence to conditional implant guidelines as well as a rapid and effective response to adverse events.
Study Reveals Significant Prevalence of Abnormal PET/MRI and Dual-Energy CT Findings with Long Covid
July 22nd 2025In a prospective study involving nearly 100 patients with Long Covid, 57 percent of patients had PET/MRI abnormalities and 90 percent of the cohort had abnormalities on dual-energy CT scans.
The Reading Room Podcast: Current and Emerging Insights on Abbreviated Breast MRI, Part 2
July 23rd 2025In the second part of a multi-part podcast episode, Stamatia Destounis, MD, Emily Conant, MD and Habib Rahbar, MD, discuss key sequences for abbreviated breast MRI and how it stacks up to other breast cancer screening modalities.
Stroke MRI Study Assesses Impact of Motion Artifacts Upon AI and Radiologist Lesion Detection
July 16th 2025Noting a 7.4 percent incidence of motion artifacts on brain MRI scans for suspected stroke patients, the authors of a new study found that motion artifacts can reduce radiologist and AI accuracy for detecting hemorrhagic lesions.